Changes in ET-related symptom burden during year 1 of the MAJIC-ET trial. (A) A waterfall plot of maximum percentage change in the MPN-10 TSS score; dotted line indicates 50% reduction in TSS. (B) The mean MPN-10 TSS throughout the first year of the trial; there was a consistent trend for reduction for ruxolitinib. (C) The mean MPN-10 score for itching during the first 12 months of the MAJIC-ET trial. See Figure 3 in the article by Harrison et al beginning on page 1889.